medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 6

<< Back Next >>

Ann Hepatol 2013; 12 (6)

Hepatitis E virus: new faces of an old infection

Riveiro-Barciela M, Rodríguez-Frías F, Buti M

Language: English
References: 94
Page: 861-870
PDF size: 141.58 Kb.


ABSTRACT

Hepatitis E virus is one of the most common causes of acute hepatitis worldwide, with the majority of cases occurring in Asia. In recent years, however, an increasing number of acute and chronic hepatitis E virus infections have been reported in industrialized countries. The importance of this infection resides in the associated morbidity and mortality. In acute cases, a high mortality rate has been reported in patients with previously undiagnosed alcoholic liver disease. Hepatitis E infection can become chronic in immunocompromised patients, such as solid organ transplant recipients, patients receiving chemotherapy, and HIV-infected patients, and lead to the development of hepatic fibrosis and cirrhosis. Hence, treatment strategies involving reductions in immunosuppressive regimens and therapy with ribavirin or peg-interferon have been evaluated. In terms of prevention, a promising new vaccine was recently licensed in China, although its efficacy is uncertain and potential adverse effects in risk groups such as chronic liver disease patients and pregnant women require investigation. In conclusion, physicians should be aware of hepatitis E as a cause of both acute and chronic hepatitis in immunocompromised patients. The best treatment option for HEV infection remains to be defined, but both ribavirin and peg-interferon may have a role in therapy for this condition.


REFERENCES

  1. WHO. Viral Hepatitis Statement A62/22. Available from: http:/apps.who.int/gb/ebwha/pdf_files/A62/A62_22-en.pdf

  2. Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol 2008; 48: 494-503.

  3. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008; 8: 698-709.

  4. Vishwanathan R. Infectious hepatitis in Delhi (1955–56), a critical study: epidemiology. Indian J Med Res 1957; 45: 49-58.

  5. Balayan MS, Andjaparidze AG, Savinskaya SS, Ketiladze ES, Braginsky, DM, Savinov AP, Poleschuk VF. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecaloral route. Intervirology 1983; 20: 23-31.

  6. Bihl F, Negro F. Hepatitis E virus: a zoonosis adapting to humans. J Antimicrob Chemother 2010; 65: 817-21.

  7. Kamar N, Selves J, Mansuy JM, Ouezzani L, Péron JM, Guitard J, Cointault O, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358: 811-7.

  8. Gérolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med 2008; 358: 859-60.

  9. Gérolami R, Moal V, Picard C, Colson P. Hepatitis E virus as an emerging cause of chronic liver disease in organ transplant recipients. J Hepatol 2009; 50: 622-4.

  10. Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, Dumortier J, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011; 140: 1481-9.

  11. Halac U, Béland K, Lapierre P, Patey N, Ward P, Brassard J, Houde A, et al. Chronic hepatitis E infection in children with liver transplantation. Gut 2012; 61: 597-603.

  12. Haagsma EB, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH, Koopmans MP. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 2008; 14: 547-53.

  13. Mallet V, Nicand E, Sultanik P, Chakvetadze C, Tessé S, Thervet E, Mouthon L, et al. Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med 2010; 153: 85-9.

  14. Pischke S, Stiefel P, Franz B, Bremer B, Suneetha PV, Heim A, Ganzenmueller T, et al. Chronic hepatitis e in heart transplant recipients. Am J Transplant 2012; 12: 3128-33.

  15. Kamar N, Rostaing L, Abravanel F, Garrouste C, Lhomme S, Esposito L, Basse G, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology 2010; 139: 1612-8.

  16. Chaillon A, Sirinelli A, De Muret A, Nicand E, d’Alteroche L, Goudeau A. Sustained virologic response with ribavirin in chronic hepatitis E virus infection in heart transplantation. J Heart Lung Transplant 2011; 30: 841-3.

  17. Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis e virus infection. Gastroenterology 2012; 142: 1388-97.

  18. Kamar N, Weclawiak H, Guilbeau-Frugier C, Legrand-Abravanel F, Cointault O, Ribes D, Esposito L, et al. Hepatitis E virus and the kidney in solid-organ transplant patients. Transplantation 2012; 93: 617-23.

  19. de Niet A, Zaaijer HL, ten Berge I, Weegink CJ, Reesink HW, Beuers U. Chronic hepatitis E after solid organ transplantation. Neth J Med 2012; 70: 261-6.

  20. Koning L, Pas SD, de Man RA, Balk AH, de Knegt RJ, ten Kate FJ, Osterhaus AD, et al. Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. J Heart Lung Transplant 2013; 32: 78-85.

  21. Riezebos-Brilman A, Puchhammer-Stöckl E, van der Weide HY, Haagsma EB, Jaksch P, Bejvl I, Niesters HG, et al. Chronic hepatitis E infection in lung transplant recipients. J Heart Lung Transplant 2013; 32: 341-6.

  22. Pischke S, Hardtke S, Bode U, Birkner S, Chatzikyrkou C, Kauffmann W, Bara CL, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int 2013; 33: 722-6.

  23. Alric L, Bonnet D, Palacin A, Thébault S, Peron JM, Sigur N, Nicot F, et al. Comparison of virological response between ribavirin and Peg-interferon monotherapy during autochtonous chronic hepatitis E virus infection. J Hepatol 2013; 58: S499.

  24. Colson P, Kaba M, Moreau J, Brouqui P. Hepatitis E in an HIV-infected patient. J Clin Virol 2009; 45: 269-71.

  25. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009; 361: 1025-7.

  26. Dalton HR, Keane FE, Bendall R, Mathew J, Ijaz S. Treatment of chronic hepatitis E in a patient with HIV infection. Ann Intern Med 2011; 155: 479-80.

  27. Kenfak-Foguena A, Schöni-Affolter F, Bürgisser P, Witteck A, Darling KE, Kovari H, Kaiser L, et al, and the Data Center of the Swiss HIV Cohort Study, Lausanne, Switzerland. Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland. Emerg Infect Dis 2011; 17: 1074–8.

  28. Crum-Cianflone NF, Curry J, Drobeniuc J, Weintrob A, Landrum M, Ganesan A, Bradley W, et al; Infectious Disease Clinical Research Program HIV Working Group. Hepatitis E virus infection in HIV-infected persons. Emerg Infect Dis 2012; 18: 502-6.

  29. Curry JA, Adams N, Crum-Cianfl one NF. Acute hepatitis E infection in an HIV-infected person in the United States. Ann Intern Med 2009; 150: 226-7.

  30. Keane F, Gompels M, Bendall R, Drayton R, Jennings L, Black J, Baragwanath G, et al. Hepatitis E virus coinfection in patients with HIV infection. HIV Med 2012; 13: 83-8.

  31. Renou C, Lafeuillade A, Cadranel JF, Pavio N, Pariente A, Allègre T, Poggi C, et al. Hepatitis E virus in HIV-infected patients. AIDS 2010; 24: 1493-9.

  32. Madejón A, Vispo E, Bottecchia M, Sánchez-Carrillo M, García-Samaniego J, Soriano V. Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. J Viral Hepat 2009; 16: 895-6.

  33. Jardi R, Crespo M, Homs M, Van den Eynde E, Girones R, Rodriguez-J, Caballero A, et al. HIV, HEV and cirrhosis: evidence of a possible link from eastern Spain. HIV Med 2012; 13: 379-83.

  34. Péron JM, Mansuy JM, Récher C, Bureau C, Poirson H, Alric L, Izopet J, et al. Prolonged hepatitis E in an immunocompromised patient. J Gastroenterol Hepatol 2006; 21: 1223-4.

  35. Tamura A, Shimizu YK, Tanaka T, Kuroda K, Arakawa Y, Takahashi K, Mishiro S, et al. Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol Res 2007; 37: 113-20.

  36. Alric L, Bonnet D, Beynes-Rauzy O, Izopet J, Kamar N. Definitive clearance of a chronic hepatitis E virus infection with ribavirin treatment. Am J Gastroenterol 2011; 106: 1562-3.

  37. Ollier L, Tieulie N, Sanderson F, Heudier P, Giordanengo V, Fuzibet JG, Nicand E. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med 2009; 150: 430-1.

  38. De Silva S, Hassan-Ibrahim MO, Austin M, Newport M, Verma S. Hepatitis E infection is an under recognized cause of acute decompensation in patients with chronic liver disease. Dig Liver Dis 2012; 44: 930-4.

  39. Goyal R, Kumar A, Panda SK, Paul SB, Acharya SK. Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report. Antivir Ther 2012; 17: 1091-6.

  40. Borkakoti J, Hazam RK, Kar P. Hepatitis E virus: A hidden danger in acute on chronic liver failure. J Hepatol 2013; 58: S499-S500.

  41. Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, Bradley DW. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 1990; 247: 1335-9.

  42. Tam AW, Smith MM, Guerra ME, Huang CC, Bradley DW, Fry KE, Reyes GR. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 1991; 185: 120-31.

  43. Xing L, Li TC, Mayakaki N, Simon MN, Wall JS, Moore M, Wang CY, et al. Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J Biol Chem 2010; 285: 33175-83.

  44. Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol 2006; 16: 5-36.

  45. Meng XJ, Purcell RH, Halbur PG, Lehman JR, Webb DM, Tsareva TS, Haynes JS, et al. A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci USA 1997; 94: 9860-5.

  46. Colson P, Romanet P, Moal V, Borentain P, Purgus R, Benezech A, Motte A, et al. Autochthonous infections with hepatitis e virus genotype 4, France. Emerg Infect Dis 2012; 18: 1361-4.

  47. Jeblaoui A, Haim-Boukobza S, Pause S, Mokhtari C, Nicand E, Roque-Afonso AM. Emerging hepatitis E genotype 4 infection in France. J Hepatol 2013; 58: S405.

  48. Colson P, Coze C, Gallian P, Henry M, De Micco P, Tamalet C. Transfusion-associated hepatitis E, France. Emerg Infect Dis 2007; 13: 648-9.

  49. Boxall E, Herborn A, Kochethu G, Pratt G, Adams D, Ijaz S, Teo CG. Transfusion-transmitted hepatitis E in a ‘nonhyperendemic’ country. Transfus Med 2006; 16: 79-83.

  50. Matsubayashi K, Kang JH, Sakata H, Takahashi K, Shindo M, Kato M, Sato S, et al. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion 2008; 48: 1368-75.

  51. Haïm-Boukobza S, Ferey MP, Vétillard AL, Jeblaoui A, Pélissier E, Pelletier G, Teillet L, et al. Transfusion-transmitted hepatitis E in a misleading context of autoimmunity and drug-induced toxicity. J Hepatol 2012; 57: 1374-8.

  52. Schlosser B, Stein A, Neuhaus R, Pahl S, Ramez B, Krüger DH, Berg T, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol 2012; 56: 500-2.

  53. Colson P, Borentain P, Queyriaux B, Kaba M, Moal V, Gallian P, Heyries L, et al. Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis 2010; 202: 825-34.

  54. Tei S, Kitajima N, Takahashi K, Mishiro S. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 2003; 362: 371-3.

  55. Izopet J, Dubois M, Bertagnoli S, Lhomme S, Marchandeau S, Boucher S, Kamar N, et al. Hepatitis e virus strains in rabbits and evidence of a closely related strain in humans, France. Emerg Infect Dis 2012; 18: 1274-81.

  56. Johne R, Heckel G, Plenge-Bönig A, Kindler E, Maresch C, Reetz J, Schielke A, et al. Novel hepatitis E virus genotype in Norway rats, Germany. Emerg Infect Dis 2010; 16: 1452-5.

  57. Johne R, Dremsek P, Kindler E, Schielke A, Plenge-Bönig A, Gregersen H, Wessels U, et al. Rat hepatitis E virus: geographical clustering within Germany and serological detection in wild Norway rats (Rattus norvegicus). Infect Genet Evol 2012; 12: 947-56.

  58. Lack JB, Volk K, Van Den Bussche RA. Hepatitis e virus genotype 3 in wild rats, United States. Emerg Infect Dis 2012; 18: 1268-73.

  59. Geng Y, Zhao C, Song A, Wang J, Zhang X, Harrison TJ, Zhou Y, et al. The serological prevalence and genetic diversity of hepatitis E virus in farmed rabbits in China. Infect Genet Evol 2011; 11: 476-82.

  60. Zhao C, Ma Z, Harrison TJ, Feng R, Zhang C, Qiao Z, Fan J, et al. A novel genotype of hepatitis E virus prevalent among farmed rabbits in China. J Med Virol 2009; 81: 1371-9.

  61. Takahashi M, Nishizawa T, Sato H, Sato Y, Jirintai, Nagashima S, Okamoto H. Analysis of the full-length genome of a hepatitis E virus isolate obtained from a wild boar in Japan that is classifiable into a novel genotype. J Gen Virol 2011; 92: 902-8.

  62. Sato Y, Sato H, Naka K, Furuya S, Tsukiji H, Kitagawa K, Sonoda Y, et al. A nationwide survey of hepatitis E virus (HEV) infection in wild boars in Japan: identification of boar HEV strains of genotypes 3 and 4 and unrecognized genotypes. Arch Virol 2011; 156: 1345-58.

  63. Galiana C, Fernández-Barredo S, García A, Gómez MT, Pérez- Gracia MT. Occupational exposure to hepatitis E virus (HEV) in swine workers. Am J Trop Med Hyg 2008; 78: 1012-5.

  64. Rodriguez-Manzano J, Miagostovich M, Hundesa A, Clemente-Casares P, Carratala A, Buti M, Jardi R, et al. Analysis of the evolution in the circulation of HAV and HEV in eastern Spain by testing urban sewage samples. J Water Health 2010; 8: 346-5.

  65. Berto A, Martelli F, Grierson S, Banks M. Hepatitis e virus in pork food chain, United kingdom, 2009-2010. Emerg Infect Dis 2012; 18: 1358-60.

  66. Di Bartolo I, Diez-Valcarce M, Vasickova P, Kralik P, Hernandez M, Angeloni G, Ostanello F, et al. Hepatitis E virus in pork production chain in Czech Republic, Italy, and Spain, 2010. Emerg Infect Dis 2012; 18: 1282-9.

  67. Bhatia V, Singhal A, Panda SK, Acharya SK. A 20-year single- center experience with acute liver failure during pregnancy: is the prognosis really worse? Hepatology 2008; 48: 1577-85.

  68. Khuroo MS, Kamili, Jameel S. Vertical transmission of hepatitis E virus. Lancet 1995; 345: 1025-6.

  69. Aggarwal R, Naik S. Epidemiology of hepatitis E: Current status. J Gastroentgerol Hepatol 2009; 24: 1484-93.

  70. Kamar N, Mansuy JM, Cointault O, Selves J, Abravanel F, Danjoux M, Otal P, et al. Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients. Am J Transplant 2008; 8: 1744-8.

  71. Hamid S, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, Siddiqui A, et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 2002; 36: 474-8.

  72. Gerolami R, Moal V, Picard C, Colson P. Hepatitis E virus as an emerging cause of chronic liver disease in organ transplant recipients. J Hepatol 2009; 50: 622-4.

  73. Abravanel F, Mansuy JM, Huynh A, Kamar N, Alric L, Peron JM, Récher C, et al. Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. J Clin Virol 2012; 54: 152-5.

  74. Koenecke C, Pischke S, Heim A, Raggub L, Bremer B, Raupach R, Buchholz S, et al. Chronic hepatitis E in hematopoietic stem cell transplant patients in a low-endemic country? Transpl Infect Dis 2012; 14: 103-6.

  75. Legrand-Abravanel F, Kamar N, Sandres-Saune K, Garrouste C, Dubois M, Mansuy JM, Muscari F, et al. Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis 2010; 202: 835-44.

  76. Sood A, Midha V, Sood N. Guillain-Barré syndrome with acute hepatitis E. Am J Gastroenterol 2000; 95: 3667-8.

  77. Kamar N, Bendall RP, Peron JM, Cintas P, Prudhomme L, Mansuy JM, Rostaing L, et al. Hepatitis E Virus and neurologic disorders. Emerg Infect Dis 2011; 17: 173-9.

  78. Del Bello A, Arné-Bes MC, Lavayssière L, Kamar N. Hepatitis E virus-induced severe myositis. J Hepatol 2012; 57: 1152-3.

  79. Fourquet E, Mansuy JM, Bureau C, Recher C, Vinel JP, Izopet J, Péron JM. Severe thrombocytopenia associated with acute autochthonous hepatitis E. J Clin Virol 2010; 48: 73-4.

  80. Li C, Wang HF. Hepatitis E virus-related acute liver failure associated with pure red cell aplasia. Hepatobiliary Pancreat Dis Int 2011; 10: 557-8.

  81. Shah SA, Lal A, Idrees M, Hussain A, Jeet C, Malik FA, Iqbal Z, et al. Hepatitis E virus-associated aplastic anaemia: the first case of its kind. J Clin Virol 2012; 54: 96-7.

  82. Khudyakov Y, Kamili S. Serological dianostics of hepatitis E virus infection. Virus Res 2011; 161: 84-92.

  83. Aggarwal R. Clinical presentation of hepatitis E. Virus Res 2011; 161: 15-22.

  84. Kamar N, Garrousgte C, Haagsma EB, Garrigue V, Pischke S, Chauvert C, Dumortier J, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011; 140: 1481-9.

  85. Gerolami R, Borentain P, Raissouni F, Motte A, Solas C, Colson P. Treatment of severe acute hepatitis E by ribavirin. J Clin Virol 2011; 52: 60-2.

  86. Péron JM. Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: A role for ribavirin? J Hepat 2011; 54: 1323-4.

  87. Péron JM, Bureau C, Poirson H, Mansuy JM, Alric L, Selves J, Dupuis E, et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat 2007; 14: 298-303.

  88. Dalton HR, Hazeldine S, Banks M, Ljaz S, Bendall R. Locally acquired hepatitis E in chronic liver disease. Lancet 2007; 369: 1260.

  89. Barnaud E, Rogée S, Garry P, Rose N, Pavio N. Thermal inactivation of infectious hepatitis E virus in experimentally contaminated food. Appl Environ Microbiol 2012; 78: 5153-9.

  90. Xu C, Alter HJ. An assessment of HEV prevalence and risk in U.S. blood donors and recipients. Available from: (http://www3.niddk.nih.gov/fund/other/HepE2012/HepatitisE2012ProgramBook.pdf

  91. Zhou YH, Purcell RH, Emerson SU. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus. Vaccine 2005; 23: 3157-65.

  92. Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa N, Myint KS, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356: 895-903.

  93. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902.

  94. Wu T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, Zhang J, Xia NS. Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology 2012; 55: 2038.




2020     |     www.medigraphic.com